Equity research

Aktiespararna: Active Biotech: “Planering för kommande studier” (in Swedish)

Redeye: Active Biotech Q4 2023: Three Externally Funded Trials in 2024

Aktiespararna: Analysis Active Biotech: “Nytt fokus i kommande studier” (in Swedish)

Aktiespararna: Analysis Active Biotech: “Fokus på nytt område” (in Swedish)

Aktiespararna: Analysis Active Biotech: “Översyn av portföljen” (in Swedish)

Redeye: Active Biotech Q1 2023: New Results from naptumomab

Redeye: Active Biotech: Interim Phase Ib Results from NeoTX

Aktiespararna: Analysis Active Biotech: “Vägskäl närmar sig” (in Swedish)

Redeye: Active Biotech Q4 2022: Laquinimod Ready for Phase II 2023-02-09

Redeye: Active Biotech: Positive Phase I Results

Aktiespararna: Analysis Active Biotech: “NAP-projekt avancerar” (in Swedish)

Redeye: Active Biotech Q3 2022: Approaching important milestones

Aktiespararna: Analysis Active Biotech: “Ögonstudie utökas” (in Swedish)

Redeye: Active Biotech Q1’22: Our comments and updated valuation

Aktiespararna: Analysis Active Biotech: “Nya steg mot avtal” (in Swedish)

Aktiespararna: Analysis Active Biotech: “Breddad klinisk portfölj” (in Swedish)

Redeye: Advancing Three Active Projects

Aktiespararna: Analysis Active Biotech: “Effektsignal i fas 1” (in Swedish)

Sverige Aktiesparares Riksförbund: Ny plan för ögonstudie (in Swedish)

Sverige Aktiesparares Riksförbund: Siktet inställt på nya mål (in Swedish)

Redeye: Derisked and Repurposed